Furthermore, crizotinib is a kinase inhibitor for multiple lung cancer oncogene including ALK, c-Met, and ROS1, especially for ROS1-rearranged NSCLC [60]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.